anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Tailoring the biliopancreatic limb length in one anastomosis gastric bypass is proposed as beneficial in retrospective studies, yet randomized trials are lacking. The aim of this double-blind, single-centre RCT was to ascertain whether tailoring biliopancreatic limb length based on total small bowel length (TSBL) results in superior outcomes after one anastomosis gastric bypass compared with a fixed 150 cm biliopancreatic limb length.
METHODS: Eligible patients, meeting International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) criteria for metabolic bariatric surgery, scheduled for primary one anastomosis gastric bypass surgery, and willing to be randomized, underwent TSBL measurement during surgery. When TSBL measurement was feasible, patients were randomly assigned to a standard 150 cm biliopancreatic limb length or a tailored biliopancreatic limb based on TSBL: TSBL less than 500 cm, biliopancreatic limb 150 cm; TSBL 500-700 cm, biliopancreatic limb 180 cm; and TSBL greater than 700 cm, biliopancreatic limb 210 cm. The primary outcome was percentage total weight loss at 5 years.
RESULTS: Between September 2020 and August 2022, 212 patients were randomized into the standard biliopancreatic limb group (105 patients) or the tailored biliopancreatic limb group (107 patients). The mean(s.d.) TSBL was 657(128) cm (range 295-1020 cm). In the tailored group, 150, 180, and 210 cm biliopancreatic limb lengths were applied to 8.4%, 53.3%, and 38.3% of patients respectively. The mean(s.d.) 1-year percentage total weight loss was 32.8(6.9)% in the standard group and 33.1(6.2)% in the tailored group (P = 0.787). Nutritional deficiencies and short-term complications showed no significant differences.
CONCLUSION: Tailoring biliopancreatic limb length based on TSBL is safe and feasible. One year after surgery, it is not superior to a standard biliopancreatic limb length of 150 cm in terms of percentage total weight loss.
REGISTRATION NUMBER: Dutch Trial Register, NL7945.
The Walnut Healthcare Global System is a creative tool to achieve maximum productivity through increasing health literacy involving multi-talented groups of people and technology working together to achieve the best results to reduce healthcare costs. Together with discovering the drivers of spending and spending growth in US health care. How do the organization’s strategy and decision-making processes impact total spending and value, and how to control them? Lifelong educational offerings that develop management competencies and improving professional skills are vital to succeed through this tool.The Self Power can be learned, it is that kind of power that helps you see things through your inner eye. For “The Self Power” to work, organizations need to create an environment that encourages creativity and innovation. After that, they should focus on bringing together multi-talented groups of individuals who collaborate to exchange ideas and knowledge to shape the direction of the future.
Tamibarotene is a synthetic retinoid that inhibits tumor cell proliferation and promotes differentiation. We previously reported on the safety and tolerability of tamibarotene in patients with recurrent or refractory solid tumors. Therefore, in this study, we aimed to evaluate the pharmacokinetic properties of tamibarotene and construct a precise pharmacokinetic model. We also conducted a non-compartmental analysis and population pharmacokinetic (popPK) analysis based on the results of a phase I study. Targeted pediatric and young adult patients with recurrent or refractory solid tumors were administered tamibarotene at doses of 4, 6, 8, 10, and 12 g/m2/day. Serum tamibarotene concentrations were evaluated after administration, and a popPK model was constructed for tamibarotene using Phoenix NLME. During model construction, we considered the influence of various parameters (weight, height, body surface area, and age) as covariates. Notably, 22 participants were included in this study, and 109 samples were analyzed. A two-compartment model incorporating lag time was selected as the base model. In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory.
TDCS will be administered with NeurConn1 Channel DC-Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes at 2mA with a 15-s ramp-up and ramp-down period. Excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks.
FIELD: cosmetics. SUBSTANCE: proposed cosmetic composition contains mixture of at least two compounds which are chosen of group containing aliphatic carboxylic acids with uneven number of carbon atoms and their derivatives. Said composition also contains alcohol having two or three carbon atoms, quantity of said alcohol being at least 30 mass % of total mass of composition. Desired composition is highly soluble and has high stability at low temperature. Said composition has high activity, stimulates growth of hair. EFFECT: improves quality of desired product. 12 tbl
Insecticidal and insect sterilant compositions comprise as the active ingredient the antibiotic Pactamycin.  The compositions may also comprise a solid or liquid carrier comprising an insect nutriment or food, and optionally an insect attractant may be included in the compositions.  Examples of suitable insect nutriments include carbohydrates, e.g. sugars (such as lactose, sucrose, fructose and glucose), starches, pectins, dextrins, corn meal, bran, pomace, corn syrup, honey and molasses; and proteins or degradation products thereof (such as egg albumen, meats, soybean oil meal, cottage cheese, proteoses, peptones, peptides and powdered milk or egg), and the insect attractant may be rec-butyl 6-methyl-3-cyclohexene-1-carboxylate, rec-butyl 4 (or 5)-chloro-6 - methyl-cyclohexane-carboxylate, methyleugenol, 4-(p-acetoxyphenyl)-2-butanone or anisylacetone.  The compositions may also be in the form of dusts containing an inert dusting powder; aqueous spray formulations comprising a wetting agent and/or spreading agent, dispersing agent, sticker or adhesive; wettable powders containing a surfactant and a dusting powder; emulsifiable concentrates comprising a concentrated organic solution in a solvent, e.g. acetone, ethyl acetate, dimethylformamide, dimethyl sulphoxide, acetonitrile and cyclohexanone, and a surfactant; or aqueous or organic solutions, e.g. in methanol, ethanol, acetone or ethylene dichloride. Harmful insect pests are combated by bringing pactamycin or compositions thereof into contact with said insects or their environment.
Acetazolamide will be prescribed in unembellished white capsules of 250 mg. The drug will be administered twice daily in the morning and evening (approximately one hour before bedtime). The total treatment length will amount to 16 weeks. In case of side effects hampering treatment adherence, the daily dosage will be reduced to a single evening dose of 250 mg.
In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
The expression of clock genes has been observed to be impaired in biopsies from patients with inflammatory bowel disease (IBD). Disruption of circadian rhythms, which occurs in shift workers, has been linked to an increased risk of gastrointestinal diseases, including IBD. The peripheral circadian clock in intestinal epithelial cells (IECs) was previously shown to balance gastrointestinal homeostasis by regulating the microbiome. Here, we demonstrated that the intestinal clock is disrupted in an IBD-relevant mouse model (IL-10-/-). A lack of the intestinal clock gene (Bmal1) in intestinal epithelial cells (IECs) in a chemically and a novel genetically induced colitis model (DSS, Bmal1IEC-/-xIL-10-/-) promoted colitis and dramatically reduced survival rates. Germ-free Bmal1IEC-/- mice colonized with disease-associated microbiota from IL-10-/- mice exhibited increased inflammatory responses, highlighting the importance of the local intestinal clock for microbiota-induced IBD development. Targeting the intestinal clock directly by timed restricted feeding (RF) in IL-10-/- mice restored intestinal clock functions, including immune cell recruitment and microbial rhythmicity; improved inflammatory responses; dramatically enhanced survival rates and rescued the histopathological phenotype. In contrast, RF failed to improve IBD symptoms in Bmal1IEC-/-xIL-10-/- mice, demonstrating the significance of the intestinal clock in determining the beneficial effect of RF. Overall, we provide evidence that intestinal clock dysfunction triggers host immune imbalance and promotes the development and progression of IBD-like colitis. Enhancing intestinal clock function by RF modulates the pathogenesis of IBD and thus could become a novel strategy to ameliorate symptoms in IBD patients.
The present invention relates to an immunogenic composition comprising at least one protein from TLP or a fragment thereof, and in particular to the compositions wherein said fragments can comprise at least one of the peptides claimed as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3 in the European Patent No. 9391641.0, or the peptide claimed as SEQ ID NO. 1 in the Italian Patent Application No. RM96A000496, suitable in therapy against tumoral diseases, and in particular against NSCLC and uro-genital cancer.
PROBLEM TO BE SOLVED: To obtain a one pack type hair-treating agent composition capable of dyeing hair in a light color, excellent in the ageing stability of a dye and capable of being easily used by compounding a specific kind of the dye, an oxidizing agent and an acid and setting the pH of the mixture to an acidic region. SOLUTION: One or more kinds of dyes selected from the green dye No.3, the black dye No.401, the violet dye No.401, the orange dye No. 205, the yellow dye No.4, the yellow dye No.402, etc., an oxidizing agent (e.g. hydrogen peroxide), and an acid (e.g. phosphoric acid, lactic acid) are compounded with each other and controlled to a pH of 1.5-5, especially 1.5-4. The dye is preferably compounded in an amount of 0.001-5wt.%, especially 0.1-1.0wt.%, based on the whole amount of the composition. The oxidizing agent is preferably compounded in an amount of approximately 0.5-10wt.%, especially approximately 1-6wt.%, An oxidation stabilizer (e.g. sodium stannate) is preferably further added to the system in an amount of approximately 0.01-2wt.%, especially approximately 0.05-1wt.%.
TBI is a significant health problem mainly because of its plausible prolonged sequelae and lack of objective measures for recovery. The conventional treatment after a TBI is physical rehabilitation that helps with motor functional recovery. However, there are usually some disabling persistent post-TBI symptoms (mostly neurological) that do not respond to the current clinical and physical rehabilitation. rTMS, on the other hand, is a promising, well-tolerated, non-invasive brain neuromodulation technique that has emerged as a therapeutic tool for a variety of neurological conditions. Thus, the researchers' aim to investigate the effect of rTMS treatment on post-TBI symptoms in patients identified by the medical collaborators (Drs. Mansouri and Salter). Equally important is to have an objective measure of treatment efficacy and patient's symptoms recovery. EVestGTM is a noninvasive technique to record neural activity from the vestibular apparatus and vestibular nuclei in the external ear. After a head injury, people commonly experience balance (vestibular) problems and dizziness, as well as confused thinking. Considering the well-known bidirectional anatomical links of the vestibular system, following an impact TBI, EVestG signals are expected to change, and our pilot studies show a great potential of EVestG to monitor the impact of TBI. Thus, the researchers aim to use EVestG as an objective measure to monitor the recovery path during and after the rTMS treatment in parallel to clinical and neuro-psychological assessments.
Administration of amino acids solutions at excessive rates or to patients with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Conservative doses of amino acids should be given to these patients, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid administration should be discontinued and the patient's clinical status re-evaluated.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
A device houses a lyophilized drug that is to be reconstituted and administered to a patient that has a disease. The device has a transparent cylinder that has a volume of at least 250 mL and that is configured to house the lyophilized drug. The cylinder has a first end that has a first spike, and the first end is opposite a second end that has a port. The first spike is configured to pierce an IV fluid bag and to form a fluid connection between the cylinder and the IV fluid bag. The port is configured to be pierced by a second spike that is part of a tubing, thereby forming a fluid connection between the cylinder and the tubing. At least a portion of the volume of the cylinder is occupied by at least 5 grams of the lyophilized drug.
PROBLEM TO BE SOLVED: To prove a medication directory editing system for reducing a cost which is required for generating a medication directory and also to provide a program for editing the medication directory. SOLUTION: When an IC card stored with prescription information is inserted (Yes in S1), prescription information is read (S2) and prescription information where a prescription date is not entered is made to be a prescription data to be newly prepared (S3). Then the number of times of prescription data with contents being the same as those of prescription data to be newly prepared are calculated in prescription information (S4). When the number of times are six or more (Yes in S5), an editing mode is made to be a simple mode (S10). When those are three or more and less than six (Yes in S6), a standard mode is adopted (S11). In the case of less than three (No in S6), a minute mode is adopted (S7). The medication directory is generated based on the determined editing mode and the prescription information (S8) and printed out (S9).
The Teaching Healthy Responsive Parenting during Infancy to promote Vital growth and rEgulation (THRIVE 2.0) group will consist of 4 sessions delivered by the trained IBH provider, in conjunction with the 1, 2, 4, and 6 month well-child visit in primary care. The THRIVE curriculum teaches responsive parenting principles targeted to establish healthy eating, sleeping, and regulation habits for infants.
Use of serotonergic antidepressants, including TRINTELLIX, may cause symptoms of sexual dysfunction [see Adverse Reactions (6.1)]. In male patients, serotonergic antidepressant use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, use may result in decreased libido and delayed or absent orgasm.

It is important for prescribers to inquire about sexual function prior to initiation of TRINTELLIX and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.
Food Addiction is often accompanied by overweight/obesity and a host of co-morbidities. From previous pilot studies, we have determined it is difficult to treat and behavioral interventions have limited effectiveness. To better understand possible genetic relationships with food addiction, a handful of researchers have begun to examine this proposed relationship. A meta-analysis (Darrow et al., 2016) that reviewed the studies examining the association between psychiatric disorders and telomere length involved 14,827 persons. Additionally, Daubenmier et al. (2012) examined the relationships among stress, eating, and metabolic factors with telomerase activity with 47 overweight/obese women. These studies lead us to seek proof of concept, that there may be a relationship between food addiction and telomere length and to better characterize persons with and without Food Addiction to enable us to develop interventions specific to each group. In this pilot we will attempt to provide additional scientific knowledge to confirm/support or negate the hypothesis that telomere length may be related to/contributing to Food Addiction. Davis (2019) conducted a review of literature involving food addiction and genetics. In the review, it is noted that thus far there has been only one study that has assessed whether genetic determinants of food addiction overlapped with drug addiction. Two loci (rs75038630 and 74902201) met GW-significance. However, neither of those loci has previously been associated with eating behaviors. We will examine telomere length in our pilot to provide additional evidence for this gap in the knowledge.

The liquid saliva sample kit that will be used is the Oragene saliva DNA collection kit. See following for more specific information.A 2 mL sample of liquid saliva will be obtained by participants spitting into the Oragene saliva DNA collection kit (Genotek Inc. Ottawa, ON, Canada) containing 1 mL of DNA stabilizing liquid. The samples will stored at room temperature until processing for DNA extraction. The saliva samples will be shipped to a laboratory at the University of California San Francisco where the telomere length will be measured by using the monoplex quantitative polymerase chain reaction (qPCR) method. This method has been validated against the Southern blot method. Stout et al. (2017) ran the inter-assay variability test and found that the average coefficient of variation was 2.7% for saliva DNA. Both the saliva collection kit and the telomere length measurement are used only for research purposes (i.e., not commercially available). Stout et al. (2017) report that salivary telomere length was correlated with whole blood telomere length (r = 0.56, p = 0.005).
PURPOSE:To prepare a patient card just by adding a card preparing device by transmitting patient information or data inputted in an IDT to the card preparing device, and preparing the card. CONSTITUTION:An ID(identification) terminal (IDT) 1 is connected to a picture reader 2, and the picture reader 2 is connected to a picture recorder 3. To the IDT 1, a magnetic card reader/writer 4 is connected as the card preparing device preparing the patient card. Before photographing to record the radiograph information of a patient in a stimulative phosphor sheet, in case registering photographing information, when the patient card is loaded into a main device, a card information reading means reads out the patient information. And by inputting the data of the photographing information and the like necessary for registering ID information from an input means, and by storing them in a storage means, the ID information is registered. On the other hand, a control means transmits the inputted data or the patient information to a card preparing device 4. Thus, without using other devices besides the card reader/writer, the patient card can be prepared.
An anti-pertussis vaccine comprises living bacteria of Bordetella strain EM 1964 in a pharmacologically acceptable support. Less side-effects are encountered than when using vaccines contg. killed Bordetella pertussis bacteria. The bacterial strain is registered at the state Institute for the Control of Medicines, Sofia, Bulgaria under number 321. The vaccine contains 3000,000 to 3,000,000,000 microorganisms per ml, the diluent pref. being physiological saline. It is obtd. by culturing EM 1964 for 48 hours at 37 deg.C in Borget - Genou medium and diluting with saline. It is pref. given orally in two equal doses.
The goal of replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state. The goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. The dose of Levothyroxine sodium tablets, USP that is adequate to achieve these goals depends on a variety of factors including the patient’s age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature of the condition being treated (see WARNINGS and PRECAUTIONS). Hence, the following recommendations serve only as dosing guidelines. Dosing must be individualized and adjustments made based on periodic assessment of the patient’s clinical response and laboratory parameters (see PRECAUTIONS, Laboratory Tests).

Levothyroxine sodium tablets, USP are administered as a single daily dose, preferably one-half to one-hour before breakfast. Levothyroxine sodium tablets, USP should be taken at least 4 hours apart from drugs that are known to interfere with its absorption (see PRECAUTIONS, Drug Interactions). Levothyroxine sodium tablets, USP should be taken with a full glass of water, (see Information for Patients).

Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of Levothyroxine sodium tablets, USP may not be attained for 4-6 weeks.

Caution should be exercised when administering Levothyroxine sodium tablets, USP to patients with underlying cardiovascular disease, to the elderly, and to those with concomitant adrenal insufficiency (see PRECAUTIONS).
Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if phototoxicity occurs. (See ADVERSE REACTIONS: Post-Marketing Adverse Events.)

As with any potent drug, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.

Prescribing ciprofloxacin tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.